Could a daily supplement soothe SIBO? small trial tests safety
NCT ID NCT07215676
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This pilot study tested an 8-week course of a multi-ingredient nutritional supplement (AV1PD1A) in 9 adults with hydrogen-dominant small intestinal bacterial overgrowth (SIBO). The main goal was to see if the supplement was safe and tolerable. Participants took three capsules daily and were monitored with blood tests, symptom questionnaires, and breath tests. Because this was a small, open-label trial with no placebo group, it can only hint at whether the supplement might help—not prove it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AV1PD1A (a blend of yeast fermentate, N-acetyl-glucosamine, probiotics, vitamin B12, berberine, and ginger extract)
What this could lead to
If this supplement proves safe and well-tolerated, it could point toward a new dietary approach to ease SIBO symptoms.
What could go wrong
This was a very small pilot study with only 9 participants and no comparison group. The results may not apply to everyone, and the supplement's effectiveness is still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROME (SIBO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NUNM - Helfgott Research Institute
Portland, Oregon, 97201, United States